论文部分内容阅读
探讨HBV－M阳性肺结核患者抗结核化疗对肝功能的影响.方法:采用酶联免疫吸附试验(ELISA)法检测178例肺结核患者HBV－M、观察执结核化疗中肝功能变化与HBV－M的关系.结果:178例肺结核患者中HBV－M阳性92例(51.7％)、阴性86例(48.3％)、化疗期间肝功能异常分别为34.8％和9.4％(P＜0.001).单阳祖、双阳组和三阳组肝功能异常分别为23.1％,44.4％和57.7％,三阳组显著高于单阳组和双阳组(P＜0.05)、结论HBV－M阳性肺结核患者可用含INH、RFP和P2A方案,但应并用保肝药.HBSAG(+)、HBEAG(+)、HBCAB(+)模式最好不用P2A.“,”Objective: To study the effects of antituberculosis chemotherapy on liver function in the pulmonary tuberculosis patients withpositive HBV-M. Methods: HBV-M and the liver function of 178 patients with pulmonary tuberculosis were investigated. Therelationship between the abnormal liver function and HBV-M during antituberculosis chemotherapy was observed. Results:Positive and negative fate of HBV-M among 178 patients was 51.7% and 48.3% respectively. 34.8% cases (32/92) with positiveHBV-M and 9.3% cases (8/86) with negative HBV-M showed abnormal liver function during antituberculosis chemotherapy,which showed a significant difference (P<0.01). The rate of abnormal liver function in one-positive group (HBsAg. HBeAg andHBcAb), two-positive group (HBsAg. HBeAg and HBsAg. HBcAb) and three-posihve group (HBsAg. HBeAg. HBcAb,andHBsAg. HBeAb. HBcAb) was 23.1%, 44.4% and 57.7% respectively. Comparing with the other two groups, there was a significantdifference in three-positive group (P<0.05). Conclusions: The chemotherapeutic programme of INF. RFP and PZA may bechosen for the pulmonary tuberculosis patients with positive HBV-M. PZA is not Suitable for the patients with positive HBsAg.HBeAg and HBcAb.